title: Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report.
abstract: Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder of unknown etiology and characterized by various clinical manifestations and multiple organ involvement. It has been reported in association with POEMS syndrome and can progress to Kaposi's sarcoma or malignant lymphoma. The disease runs a more aggressive course and a poor prognosis. Optimal therapies have not been well established up to now. We here reported a case of rare MCD complicated with multiple myeloma who received bortezomib and achieved very good remission. To our knowledge, this is the first report on MCD in the setting of multiple myeloma with good response to bortezomib.
authors.affiliation: Department of Hematology, Second Affiliated Hospital to Second Military Medical University, 415 Fengyang Rd, Shanghai 200003, PR China. yuanzg@163.com
authors.forename: Zhen-gang
authors.initials: ZG
authors.lastname: Yuan
authors.forename: Xiao-yi
authors.initials: XY
authors.lastname: Dun
authors.forename: Yong-hua
authors.initials: YH
authors.lastname: Li
authors.forename: Jian
authors.initials: J
authors.lastname: Hou
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D005871:Castleman Disease / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy* / Q000473:pathology; D011719:Pyrazines / Q000627:therapeutic use*; D012074:Remission Induction
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib